← SEC 公告列表 | IMMX SEC 公告 | Immix Biopharma, Inc.（IMMX）

重大事件 即時報告 8-K 2026-07-20

Immix Biopharma終止Richard Graydon僱傭關係 管理層稱不影響業務

於 SEC 網站開啟原文

AI 繁中摘要

📄 美國證券交易委員會（SEC）8-K 申報摘要 公司：Immix Biopharma, Inc.（納斯達克代碼：IMMX） 申報日期：2026 年 7 月 20 日 📌 事件重點（Item 8.01 其他事件） Immix Biopharma 於 2026 年 7 月 17 日終止了 Richard Graydon 的僱傭關係。該決定與其在公司的工作表現無關。管理層表示，由於 Graydon 在職時間極短，因此預期此人事變動對公司業務不會構成任何重大影響。 💡 對投資者的潛在影響 此項申報屬於常規人事更新，並無涉及財務數據、臨床試驗結果或監管變動。公司管理層明確認為事件不具重大性，因此投資者可視為一次非實質性的營運變動，短線股價波動風險偏低。 📅 公司背景 Immix Biopharma 為一家處於臨床階段的生物製藥公司，專注於開發針對難治性實體腫瘤的創新細胞療法。截至申報日，公司仍為「新興成長公司」（Emerging Growth Company），享有部分披露寬限。 （註：此摘要僅基於公開的 8-K 文件，不構成投資建議。）
展開英文正文 
false
 0001873835
 
 
 
 
 
 
 
 0001873835
 
 
 2026-07-20
 2026-07-20
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

WASHINGTON,
DC 20549

 

FORM
8-K

 

CURRENT
REPORT

Pursuant
to Section 13 or 15(d) of

the
Securities Exchange Act of 1934

 

Date
of report (Date of earliest event reported): July 20, 2026

 

IMMIX
BIOPHARMA, INC.

(Exact
Name of Registrant as Specified in Its Charter)

 

 
 Delaware
  
 001-41159
  
 45-4869378

 
 (State
 or Other Jurisdiction

 of
 Incorporation)

  
 (Commission

 File
 Number)

  
 (I.R.S.
 Employer

 Identification
 Number)

 
 

11400
West Olympic Blvd., Suite 200

Los
Angeles, CA 90064

(Address
of principal executive offices)

 

(310)
651-8041

(Registrant’s
telephone number, including area code)

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under
any of the following provisions.

 

 
 ☐
 Written communications
 pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 
  
  

 
 ☐
 Soliciting material pursuant
 to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

 
  
  

 
 ☐
 Pre-commencement communications
 pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

 
  
  

 
 ☐
 Pre-commencement communications
 pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 
 

Securities
registered pursuant to Section 12(b)of the Act:

 

 
 Title
 of each class
  
 Trading
 Symbol(s)
  
 Name
 of each exchange on which registered

 
 Common Stock, par value
 of $0.0001 per share
  
 IMMX
  
 The Nasdaq Stock Market
 LLC

 
 

Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

Emerging
growth company ☒

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

  

 

 

Item
8.01 Other Events.

 

As
of July 17, 2026, Richard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the
Company. Given his short tenure, management believes there is no material effect on the business.

 

  

  

 

 

SIGNATURES

 

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

 

 
  
 Immix Biopharma, Inc.

 
  
  

 
 Dated:
 July 20, 2026
 /s/
 Ilya Rachman

 
  
 Ilya
 Rachman, M.D., Ph.D.

 
  
 Chief Executive Officer